Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2,316 JPY | +0.54% | 0.00% | -7.15% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- With regards to fundamentals, the enterprise value to sales ratio is at 0.92 for the current period. Therefore, the company is undervalued.
- The company's share price in relation to its net book value makes it look relatively cheap.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company sustains low margins.
- The company is in debt and has limited leeway for investment
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Commodity Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-7.15% | 1.29B | B+ | ||
+5.92% | 104B | A- | ||
-2.51% | 64.55B | A- | ||
+51.90% | 41.5B | B | ||
+18.29% | 40.01B | B | ||
+7.47% | 33.03B | A- | ||
+10.70% | 20.11B | B- | ||
+16.99% | 17.52B | C+ | ||
+20.27% | 15.51B | B- | ||
+10.05% | 15.34B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 4061 Stock
- Ratings Denka Company Limited